Lara McGrath

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 4

Top Topics

Induced Pluripotent Stem Cells

Top Venues

Cancer research communications

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Benjamin Umiker, Yasmin Hashambhoy-Ramsay, Jeff Smith, Tanzila Rahman, Amy Mueller, Rachel Davidson, Christina Meyer, Gayatri Patankar, Mohammad Murshid Alam, Sarah Jaffe, Kristin Krukenberg, Allison Goodman, Vikki Spaulding, Michelle Priess, Abha Dhaneshwar, Masie Wong, Alexa Diiorio, Kristin O'Malley, Lara McGrath, Margaret Willer, Lauren Pepper, Monica Gostissa, Katalin Kis-Toth, Dmitri Wiederschain, Heather Cohen, Donald R Shaffer
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T Cell Activation in Tumors. Molecular cancer therapeutics (2023)
Maria Secrier, Lara McGrath, Felicia S L Ng, Sakshi Gulati, Amelia Raymond, Barret R B Nuttall, Julie Berthe, Emma V Jones, Ben S Sidders, Jerome Galon, J Carl Barrett, Helen K Angell
Immune cell abundance and T cell receptor landscapes suggest new patient stratification strategies in head and neck squamous cell carcinoma. Cancer research communications (2023)
Cascone Tina, Gozde Kar, Jonathan D Spicer, María Del Rosario García-Campelo, Walter Weder, Davey B Daniel, David R Spigel, Maen Hussein, Julien Mazieres, Júlio Oliveira, Edwin H Yau, Alexander I Spira, Valsamo Anagnostou, Raymond Mager, Oday Hamid, Lin-Yang Cheng, Ying Zheng, Jorge M Blando, Tze Heng Tan, Michael Surace, Jaime Rodriguez-Canales, Vancheswaran Gopalakrishnan, Bret R Sellman, Italia Grenga, Yee Soo-Hoo, Rakesh Kumar, Lara McGrath, Patrick M Forde
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase 2 NeoCOAST Platform Trial. Cancer discovery (2023)
Timothy Anthony Yap, Justin F Gainor, Margaret K Callahan, Gerald S Falchook, Russell K Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T Gibney, Howard A Burris, Scott S Tykodi, Osama E Rahma, Tanguy Y Seiwert, Kyriakos P Papadopoulos, Mariela Blum Murphy, Haeseong Park, Amanda Hanson, Yasmin Hashambhoy-Ramsay, Lara McGrath, Ellen Hooper, Xiaoying Xiao, Heather Cohen, Martin Fan, Daniel Felitsky, Courtney Hart, Rachel McComb, Karen Brown, Ali Sepahi, Judith Jimenez, Weidong Zhang, Johan Baeck, Haley Laken, Richard Murray, Elizabeth Trehu, Christopher J Harvey
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (17) (2022)